Duligotuzumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Duligotuzumab
Accession Number
DB12142
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Duligotuzumab has been used in trials studying the treatment of Neoplasms, Colorectal Cancer, Head and Neck Cancer, and Epithelial Tumors, Malignant.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
MEHD7945A
Categories
UNII
8PMF8YQX2T
CAS number
1314238-96-4

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Duligotuzumab.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Duligotuzumab.
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Duligotuzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Duligotuzumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Duligotuzumab.
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Duligotuzumab.
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Duligotuzumab.
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Duligotuzumab.
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Duligotuzumab.
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Duligotuzumab.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911288
Wikipedia
Duligotuzumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentEpithelial Tumors, Malignant1
1CompletedTreatmentHead and Neck Carcinoma1
1CompletedTreatmentNeoplasms1
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentHead and Neck Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 15:27 / Updated on August 02, 2018 06:34